Abstract
We previously identified 18 genes that correlated with ER positivity by adapter‐tagged competitive‐PCR analysis of 2412 genes in human breast cancer tissues. The aim of the present study was to determine the prognostic significance of these genes. mRNA expression levels of 12 of the above 18 genes were quantified in breast cancer tissues by real‐time PCR assay, and their association with patients' prognosis (n=110) was studied according to hormone receptor (HR) status. In addition, the genes found to influence prognosis were further investigated to examine whether their mRNA expression could be induced by estrogen in MCF‐7 cells in vitro. Of the 12 genes, mRNA expression levels of two [α1‐antichymotrypsin (ACT) and stanniocalcin 2 (STC2)] were significantly (P=0.002 and P=0.007, respectively) associated with good prognosis in HR‐positive (ER and/or PR positive) breast cancer patients treated with adjuvant hormone therapy. Multivariate analysis showed that ACT mRNA level, but not STC2 mRNA level, in HR‐positive patients, was a significant prognostic factor (P=0.042), which was independent of tumor size and lymph node metastases. On the other hand, mRNA expressions of ACT and STC2 were not significantly associated with prognosis in HR‐negative patients. Estradiol treatment resulted in a significant increase in the mRNA levels of both ACT and STC2 in MCF‐7 cells. The mRNA level of ACT, which is an estrogen‐inducible gene, is a significant predictor of good prognosis in HR‐positive, but not HR‐negative, patients with breast cancers. Since HR‐positive patients were treated with adjuvant hormone therapy, we suggest that ACT mRNA level could potentially be used as a predictor of response to hormone therapy, rather than a prognostic factor (predictor of metastatic potential).
Abbreviations:
- ER
estrogen receptor
- PR
progesterone receptor
References
- 1. Goldhirsch A, Wood WC, Glber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357–65. [DOI] [PubMed] [Google Scholar]
- 2. Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR, Afshari CA. Regulation of DNA replication fork genes by 17beta‐estradiol. Mol Endocrinol 2002; 16: 1215–29. [DOI] [PubMed] [Google Scholar]
- 3. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up‐ and down‐regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562–74. [DOI] [PubMed] [Google Scholar]
- 4. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S. Development of cDNA microarray for expression profiling of estrogen‐responsive genes. J Mol Endocrinol 2002; 29: 175–92. [DOI] [PubMed] [Google Scholar]
- 5. Spyratos F, Andrieu C, Hacene K, Chambon P, Rio MC. pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994; 69: 394–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Bieche I, Parfait B, Nogues C, Andrieu C, Vidaud D, Spyratos F, Lidereau R, Vidaud M. The CGA gene as new predictor of the response to endocrine therapy in ER alpha‐positive postmenopausal breast cancer patients. Oncogene 2001; 20: 6955–9. [DOI] [PubMed] [Google Scholar]
- 7. Iwao K, Matoba R, Ueno N, Ando A, Miyoshi Y, Matsubara K, Noguchi S, Kato K. Molecular classification of primary breast tumors possessing distinct prognostic properties. Hum Mol Genet 2002; 11: 199–206. [DOI] [PubMed] [Google Scholar]
- 8. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M. Quantitation of MYC gene expression in sporadic breast tumors with a real‐time reverse transcription‐PCR assay. Cancer Res 1999; 59: 2759–65. [PubMed] [Google Scholar]
- 9. Lamy PJ, Pujol P, Thezenas S, Kramar A, Rouanet P, Guilleux F, Grenier J. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy. Breast Cancer Res Treat 2002; 76: 65–71. [DOI] [PubMed] [Google Scholar]
- 10. Raemaekers JM, Beex LV, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW. Progesterone receptor activity and relapse‐free survival in patients with primary breast cancer: the role of adjuvant chemotherapy. Breast Cancer Res Treat 1987; 9: 191–9. [DOI] [PubMed] [Google Scholar]
- 11. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983; 52: 655–709. [DOI] [PubMed] [Google Scholar]
- 12. Massot O, Baskevitch PP, Capony F, Garcia M, Rochefort H. Estradiol increases the production of alpha 1‐antichymotrypsin in MCF7 and T47D human breast cancer cell lines. Mol Cell Endocrinol 1985; 42: 207–14. [DOI] [PubMed] [Google Scholar]
- 13. Kroll J, Briand P. Estrogen‐dependent release of serum proteins from MCF‐7 breast carcinoma cells in vitro . Anticancer Res 1988; 8: 89–91. [PubMed] [Google Scholar]
- 14. Finlay TH, Tamir S, Kadner SS, Cruz MR, Yavelow J, Levitz M. alpha 1‐Antitrypsin‐ and anchorage‐independent growth of MCF‐7 breast cancer cells. Endocrinology 1993; 133: 996–1002. [DOI] [PubMed] [Google Scholar]
- 15. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997; 18: 502–19. [DOI] [PubMed] [Google Scholar]
- 16. Ishibashi K, Imai M. Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am J Physiol Renal Physiol 2002; 282: F367–75. [DOI] [PubMed] [Google Scholar]
- 17. Chang AC, Jellinek DA, Reddel RR. Mammalian stanniocalcins and cancer. Endocr Relat Cancer 2003; 10: 359–73. [DOI] [PubMed] [Google Scholar]
- 18. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC, Aldaz CM. Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Res 2000; 60: 5977–83. [PubMed] [Google Scholar]
- 19. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ. Stanniocalcin 2 is an estrogen‐responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 2002; 62: 1289–95. [PubMed] [Google Scholar]